Venous thromboembolism in ANCA-associated vasculitis - Incidence and risk factors

Rheumatology

Volumn 47, Issue 4, 2008, Pages 530-534

  Stassen, P M ^a   Derks, R P H ^b   Kallenberg, C G M ^b   Stegeman, C A ^b  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ANCA associated vasculitis; Incidence; Risk factors; Venous thromboembolism

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADOLESCENT; ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; RENOVASCULAR DISEASE; RISK ASSESSMENT; RISK FACTOR; VENOUS THROMBOEMBOLISM; WEGENER GRANULOMATOSIS; AUTOIMMUNE DISEASE; BLOOD; COHORT ANALYSIS; MIDDLE AGED; RETROSPECTIVE STUDY; VASCULITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOIMMUNE DISEASES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VASCULITIS; VENOUS THROMBOEMBOLISM;

EID: 43049180067     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken035     Document Type: Article

References (26)

1. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006;367:1075-9.
2. Petri M. Hopkins Lupus Cohort. 1999 update. Rheum Dis Clin North Am 2000;26:199-213.
3. Danese S, Semeraro S, Papa A et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005;11:7227-36.
4. von Scheven E, Lu TT, Emery HM, Elder ME, Wara DW. Thrombosis and pediatric Wegener's granulomatosis: Acquired and genetic risk factors for hypercoagulability. Arthritis Rheum 2003;49:862-5.
5. Lamprecht P, deGroot K, Schnabel A, Csernok E, Liedvogel B, Gross WL. Anticardiolipin antibodies and antibodies to beta(2)-glycoprotein I in patients with Wegener's granulomatosis. Rheumatology 2000;39:568-70.
6. Merkel PA, Lo GH, Holbrook JT et al. Brief communication: High incidence of venous thrombotic events among patients with Wegener granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005;142:620-6.
7. Hansson PO, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'. Arch Intern Med 1997;157:1665-70.
8. Blann AD, Lip GY. Venous thromboembolism. Br Med J 2006;332:215-9.
9. Weidner S, Hafezi-Rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2006;55:146-9.
10. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
11. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994;87:671-8.
12. Ridker PM, Goldhaber SZ, Danielson E et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-34.
13. Somer T. Thrombo-embolic and vascular complications in vasculitis syndromes. Eur Heart J 1993;14(Suppl K):24-29.
14. Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by antineutrophil cytoplasmic antibodies. J Am Soc Nephrol 2006;17:1235-42.
15. Hergesell O, Egbring R, Andrassy K. Presence of anticardiolipin antibodies discriminates between Wegener's granulomatosis and microscopic polyarteritis. Adv Exp Med Biol 1993;336:393-6.
16. De Bandt M, Ollivier V, Meyer O et al. Induction of interleukin-1 and subsequent tissue factor expression by anti-proteinase 3 antibodies in human umbilical vein endothelial cells. Arthritis Rheum 1997;40:2030-8.
17. Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989;53:231-41.
18. Woolf AD, Wakerley G, Wallington TB, Scott DG, Dieppe PA. Factor VIII related antigen in the assessment of vasculitis. Ann Rheum Dis 1987;46:441-7.
19. Kyrle PA, Minar E, Hirschl M et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-62.
20. Jordan JM, Allen NB, Pizzo SV. Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis. Am J Med 1987;82:397-400.
21. Tsai AW, Cushman M, Rosamond WD et al. Coagulation factors, inflammation markers, and venous thromboembolism: The longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002;113:636-42.
22. Hansen KE, Moore KD, Ortel TL, Allen NB. Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa. Arthritis Rheum 1999;42:2250-2.
23. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006;118:555-68.
24. Ozsoylu S, Strauss HS, Diamond LK. Effects of corticosteroids on coagulation of the blood. Nature 1962;195:1214-5.
25. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: Effects of the disease and therapy. Thromb Res 2003;111:199-212.
26. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338S-400S.